Methamphetamine Use: A Narrative Review of Adverse Effects and Related Toxicities
Methamphetamine has been labeled “America’s most dangerous drug” and has received significant public health attention. Stimulant addiction and tolerance are heavily documented in the literature; increasingly larger doses maintain euphoria in short time periods to withstand stimulant tolerance. Stimulant deaths are high in the United States and abroad. Between 2013 and 2019, deaths related to methamphetamine use quadrupled from 3,616 to 16,127. Methamphetamine use increased four-fold from 2015 to 2016. Due to this increase in methamphetamine use and its associated medical complications, the mortality rate associated with methamphetamine use has doubled over the past ten years. Cardiopulmonary symptoms include chest pain, palpitations, and shortness of breath. Methamphetamine-related myocardial infarction can also occur. Central nervous system symptoms include agitation, anxiety, delusions, hallucinations, and seizures. Methamphetamine-induced psychosis may unmask underlying psychiatric disorders. It can also cause cerebral vasculitis, which elicits cortical blindness and ischemic strokes. Methamphetamine-induced neurotoxicity in serotonergic systems is more diffuse, involving the striatum, hippocampus, septum, amygdala, and hypothalamus leading to mood changes, psychosis, and memory impairment. This narrative review will aim to highlight the adverse effects as well as the toxicity that can occur with methamphetamine use.
1. Gonzales R, Mooney L, Rawson RA. The methamphetamine problem in the United States. Annu Rev Public Health. 2010;31:385-398. doi:10.1146/annurev.publhealth.012809.103600
2. Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. JAMA Psychiatry. 2021;78(12):1329-1342. doi:10.1001/jamapsychiatry.2021.2588
3. Jones CM, Compton WM, Mustaquim D. Patterns and Characteristics of Methamphetamine Use Among Adults-United States, 2015-2018. MMWR Morb Mortal Wkly Rep. 2020;69(12):317-323. doi:10.15585/mmwr.mm6912a1
4. Han B, Compton WM, Blanco C, Colpe LJ. Prevalence, Treatment, And Unmet Treatment Needs Of US Adults With Mental Health And Substance Use Disorders. Health Aff Proj Hope. 2017;36(10):1739-1747. doi:10.1377/hlthaff.2017.0584
5. Kipke MD, O'Connor S, Palmer R, MacKenzie RG. Street youth in Los Angeles. Profile of a group at high risk for human immunodeficiency virus infection. Arch Pediatr Adolesc Med. 1995;149(5):513-519. doi:10.1001/archpedi.1995.02170180043006
6. Smid MC, Metz TD, Gordon AJ. Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. Clin Obstet Gynecol. 2019;62(1):168-184. doi:10.1097/grf.0000000000000418
7. Blum K, Cadet JL, Gold MS. Psychostimulant use disorder emphasizing methamphetamine and the opioid-dopamine connection: Digging out of a hypodopaminergic ditch. J Neurol Sci. 2021;420:117252. doi:10.1016/i.jns.2020.117252
8. Paulus MP, Stewart JL. Methamphetamine Use Disorder: The Next Addiction Crisis. JAMA Psychiatry. 2020;77(9):959-966. doi:10.1001/jamapsychiatry.2020.0246
9. Yimsaard P, Maes MM, Verachai V, Kalayasiri R. Pattern of Methamphetamine Use and the Time Lag to Methamphetamine Dependence. J Addict Med. 2018;12(2):92-98. doi:10.1097/adm.0000000000000371
10. Vocci FJ, Appel NM. Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction. 2007;102(s1):96-106. doi:10.1111/j.1360-0443.2007.01772.x
11. Shin EJ, Dang DK, Tran TV, et al. Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors. Arch Pharm Res. 2017;40(4):403-428. doi:10.1007/s12272-017-0897-y
12. Roohbakhsh A, Shirani K, Karimi G. Methamphetamine-induced toxicity: The role of autophagy? ChemBiol Interact. 2016;260:163-167. doi:10.1016/j.cbi.2016.10.012
13. Thompson PM, Hayashi KM, Simon SL, et al. Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci Off J Soc Neurosci. 2004;24(26):6028-6036. doi:10.1523/jneurosci.0713-04.2004
14. Gorman MC, Orme KS, Nguyen NT, Kent EJ III, Caughey AB. Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol. 2014;211(4):429.e1-429.e7. doi:10.1016/j.ajog.2014.06.005
15. Kevil CG, Goeders NE, Woolard MD, et al. Methamphetamine Use and Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019;39(9):1739-1746. doi:10.1161/atvbaha.119.312461
16. Zweben JE, Cohen JB, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13(2):181-190. doi:10.1080/10550490490436055
17. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat. 2008;35(4):445-450. doi:10.1016/j.jsat.2007.12.004
18. Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addict Abingdon Engl. 2006;101(Suppl 1):76-88. doi:10.1111/j.1360-0443.2006.01592.x
19. Berman S, O'Neill J, Fears S, Bartzokis G, London ED. Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci. 2008;1141:195-220. doi:10.1196/annals.1441.031
20. Morales A, Lee B, Hellemann G, O'Neill J, London ED. Gray-Matter Volume in Methamphetamine Dependence: Cigarette Smoking and Changes with Abstinence from Methamphetamine. Drug Alcohol Depend. 2012;125(3):230-238. doi:10.1016/j.drugalcd ep.2012.02.017
21. Tobias MC, O'Neill J, Hudkins M, Bartzokis G, Dean AC, London ED. White-matter abnormalities in brain during early abstinence from methamphetamine abuse. Psychopharmacology(Berl). 2010;209(1):13-24. doi:10.1007/s00213-009-1761-7
22. Edinoff AN, Nix CA, McNeil SE, et al. Prescription Stimulants in College and Medical Students: A Narrative Review of Misuse, Cognitive Impact, and Adverse Effects. Psychiatry Int. 2022;3(3):221-235. doi:10.3390/psychiatryint3030018
23. He SY, Matoba R, Fujitani N, Sodesaki K, Onishi S. Cardiac muscle lesions associated with chronic administration of methamphetamine in rats. Am J Forensic Med Pathol. 1996;17(2):155-162. doi:10.1097/00000433-199606000-00014
24. Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008;27(3):253-262. doi:10.1080/09595230801923702
25. Wijetunga M, Seto T, Lindsay J, Schatz I. Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg? J Toxicol Clin Toxicol. 2003;41(7):981-986. doi:10.1081/clt-120026521
26. Richards JR, Wang CG, Fontenette RW, Stuart RP, McMahon KF, Turnipseed SD. Rhabdomyolysis, Methamphetamine, Amphetamine and MDMA Use: Associated Factors and Risks. J Dual Diagn. 2020;16(4):429-437. doi:10.1080/15504263.2020.1786
27. Ropek N, Al-Serori H, Misik M, et al. Methamphetamine(“crystal meth”) causes induction of DNA damage and chromosomal aberrations in human derived cells. Food Chem Toxicol. 2019;128:1-7. doi:10.1016/j.fct.2019.03.035
28. Cadet JL, Krasnova IN. Chapter 5- Molecular Bases of Methamphetamine-Induced Neurodegeneration. In: International Review of Neurobiology. Vol 88. Academic Press; 2009:101-119. doi:10.1016/s0074-7742(09)88005-7
29. Steinkellner T, Freissmuth M, Sitte HH, Montgomery T. The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine(MDMA, ‘Ecstasy’), methamphetamine and d-amphetamine. Biol Chem. 2011;392(1-2):103-115. doi:10.1515/bc.2011.016
30. Dominic P, Ahmad J, Awwab H, et al. Stimulant Drugs of Abuse and Cardiac Arrhythmias. Circ Arrhythm Electrophysiol. 2022;15(1):e010273. doi:10.1161/circep.121.010273
31. Matsumoto RR, Seminerio MJ, Turner RC, et al. Methamphetamine-induced toxicity: an updated review on issues related to hyperthermia. Pharmacol Ther. 2014;144(1):28-40. doi:10.1016/j.pharmthera.2014.05.001
32. Batra V, Murnane KS, Knox B, et al. Early onset cardiovascular disease related to methamphetamine use is most striking in individuals under 30: A retrospective chart review. Addict Behav Rep. 2022;15:100435. doi:10.1016/j.abrep.2022.100435
33. Isoardi KZ, Mudge DW, Harris K, Dimeski G, Buckley NA. Methamphetamine intoxication and acute kidney injury: A prospective observational case series. Nephrol Carlton Vic. 2020;25(10):758-764. doi:10.1111/nep.13762
34. Maheshwari M, Athiraman H. “Speedballing” to Severe Rhabdomyolysis and Hemodialysis in a 27-Year-Old Male. Cureus. 2021;13(12):e20667. doi:10.7759/cureus.20667
35. Pillai S, Cesarz B, Boulware C, Khan A. Hypotension, Severe Hyperthermia(42°C), Rhabdomyolysis, and Disseminated Intravascular Coagulation Induced by Lethal Dose of Methamphetamine. Cureus. 2019;11(7):e5245. doi:10.7759/cureus.5245
36. Darke S, Duflou J, Kaye S. Prevalence and nature of cardiovascular disease in methamphetamine-related death: A national study. Drug Alcohol Depend. 2017;179:174-179. doi:10.1016/j.drugalcdep.2017.07.001
37. Huang MC, Yang SY, Lin SK, et al. Risk of Cardiovascular Diseases and Stroke Events in Methamphetamine Users: A 10-Year Follow-Up Study. J Clin Psychiatry. 2016;77(10):1396-1403. doi:10.4088/icp.15m09872
38. Zhu Z, Osman S, Stradling D, Shafie M, Yu W. Clinical characteristics and outcomes of methamphetamine-associated versus non-methamphetamine intracerebral hemorrhage. Sci Rep. 2020;10(1):6375. doi:10.1038/s41598-020-63480-z
39. He T, Han C, Liu C, et al. Dopamine D1 receptors mediate methamphetamine-induced dopaminergic damage: involvement of autophagy regulation via the AMPK/FOXO3A pathway. Psychopharmacology(Berl). 2022;239(3):951-964. doi:10.1007/s00213-022-06097-6
40. Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE. Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology(Berl). 2012;220(3):495-508. doi:10.1007/s00213-011-2504-0
41. Yang Y, Yu X, Liu X, Liu G, Zeng K, Wang G. Altered fecal microbiota composition in individuals who abuse methamphetamine. Sci Rep. 2021;11(1):18178. doi:10.1038/s41598-021-97548-1
42. Zhao J, Shen S, Dai Y, Chen F, Wang K. Methamphetamine Induces Intestinal Inflammatory Injury via Nod-Like Receptor 3 Protein(NLRP3) Inflammasome Overexpression In Vitro and In Vivo. Med Sci Monit Int Med J Exp Clin Res. 2019;25:8515-8526. doi:10.12659/msm.920190